Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05051579 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 272
- Enrollment target
NCT05051579 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 272 participants.
The verdict
NCT05051579, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 272 participants
- Enrollment target
Study Summary
The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.
Interventions
- DRUG Placebo
- DRUG LY3502970
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2021-09-29 |
| Est. Completion | 2022-11-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05051579
The ClinicalTrials.gov registry entry for NCT05051579 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05051579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05051579 about?
NCT05051579 is a clinical study titled "A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities". The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.
What is the current status of trial NCT05051579?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 272 participants. The study started on 2021-09-29. Estimated completion is 2022-11-22.
What interventions are being tested in trial NCT05051579?
The interventions under investigation include: Placebo (DRUG), LY3502970 (DRUG).
Who is sponsoring clinical trial NCT05051579?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.